cAMP signaling plays a key role in regulating
pain sensitivity. Here, we uncover a previously unidentified molecular mechanism in which direct phosphorylation of the exchange
protein directly activated by cAMP 1 (EPAC1) by
G protein kinase 2 (GRK2) suppresses Epac1-to-Rap1 signaling, thereby inhibiting persistent inflammatory
pain. Epac1(-/-) mice are protected against inflammatory
hyperalgesia in the complete
Freund's adjuvant (CFA) model. Moreover, the
Epac-specific inhibitor
ESI-09 inhibits established CFA-induced
mechanical hyperalgesia without affecting normal mechanical sensitivity. At the mechanistic level, CFA increased activity of the
Epac target Rap1 in dorsal root ganglia of WT, but not of Epac1(-/-), mice. Using sensory neuron-specific overexpression of GRK2 or its
kinase-dead mutant in vivo, we demonstrate that GRK2 inhibits CFA-induced
hyperalgesia in a
kinase activity-dependent manner. In vitro, GRK2 inhibits Epac1-to-Rap1 signaling by phosphorylation of Epac1 at Ser-108 in the Disheveled/Egl-10/
pleckstrin domain. This phosphorylation event inhibits agonist-induced translocation of Epac1 to the plasma membrane, thereby reducing Rap1 activation. Finally, we show that GRK2 inhibits Epac1-mediated sensitization of the mechanosensor Piezo2 and that Piezo2 contributes to inflammatory
mechanical hyperalgesia. Collectively, these findings identify a key role of Epac1 in chronic inflammatory
pain and a molecular mechanism for controlling Epac1 activity and
chronic pain through phosphorylation of Epac1 at Ser-108. Importantly, using the
Epac inhibitor
ESI-09, we validate Epac1 as a potential therapeutic target for
chronic pain.